Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03326752 · ClinicalTrials.gov registry record · Phase 1
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
A Phase 1 study, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03326752: Completed Phase 1 study, sponsored by Dynavax Technologies Corporation.
NCT03326752 is a Phase 1 study that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03326752, a Phase 1 study, has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended phase 2 dose (RP2D).
Primary Outcome
Incidence of dose-limiting toxicities (DLTs)
Interventions
- DRUG DV281
- DEVICE Breath Actuated Nebulizer
- DRUG DV281 (RP2D)
- DRUG Approved Anti-PD-1 Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2019-09-19 |
| Phase | Phase 1 |
What the finished NCT03326752 record still lists
NCT03326752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 4 interventions - of which DV281 is the first listed.
NCT03326752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03326752 about?
NCT03326752 is a clinical study titled "Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC". This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended phase 2 dose (RP2D).
What is the current status of trial NCT03326752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-09-20. Estimated completion is 2019-09-19.
What interventions are being tested in trial NCT03326752?
The interventions under investigation include: DV281 (DRUG), Breath Actuated Nebulizer (DEVICE), DV281 (RP2D) (DRUG), Approved Anti-PD-1 Inhibitor (DRUG).
Who is sponsoring clinical trial NCT03326752?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03326752's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI